Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patientsWilma Barcellini, Alberto Zanella, Nicoletta Revelli et al.|Blood|2014Cited by 371
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Gianluca Gaïdano, Lodovico Terzi-di-Bergamo et al.|Blood|2015Cited by 215
<i>Pneumocystis carinii</i> pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centresLivio Pagano, A. Del Favero, Luana Fianchi et al.|British Journal of Haematology|2002Cited by 146
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studiesWilma Barcellini, Alberto Zanella, Francesco Zaja et al.|Blood|2012Cited by 144
Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centersWilma Barcellini, Agostino Cortelezzi, Anna Zaninoni et al.|American Journal of Hematology|2018Cited by 80